Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Background Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment of patients with advanced/metastatic solid tu...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 25, 2022
|
| In: |
Journal for ImmunoTherapy of Cancer
Year: 2022, Jahrgang: 10, Heft: 2, Pages: 1-13 |
| ISSN: | 2051-1426 |
| DOI: | 10.1136/jitc-2021-003776 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/jitc-2021-003776 Verlag, lizenzpflichtig, Volltext: https://jitc.bmj.com/content/10/2/e003776 
|
| Verfasserangaben: | Patrick Schöffski, Daniel SW Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak, David S Hong |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1797752944 | ||
| 003 | DE-627 | ||
| 005 | 20230428015056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220406s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2021-003776 |2 doi | |
| 035 | |a (DE-627)1797752944 | ||
| 035 | |a (DE-599)KXP1797752944 | ||
| 035 | |a (OCoLC)1341458593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schöffski, Patrick |d 1963- |e VerfasserIn |0 (DE-588)130338133 |0 (DE-627)497997185 |0 (DE-576)298135639 |4 aut | |
| 245 | 1 | 0 | |a Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies |c Patrick Schöffski, Daniel SW Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak, David S Hong |
| 246 | 3 | 0 | |a plus minus first second three one five hundred twenty five |
| 264 | 1 | |c February 25, 2022 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.04.2022 | ||
| 520 | |a Background Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment of patients with advanced/metastatic solid tumors with ieramilimab ±the anti-programmed cell death-1 antibody, spartalizumab. - Methods Eligible patients had advanced/metastatic solid tumors and progressed after, or were unsuitable for, standard-of-care therapy, including checkpoint inhibitors in some cases. Patients received ieramilimab ±spartalizumab across various dose-escalation schedules. The primary objective was to assess the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). - Results In total, 255 patients were allocated to single-agent ieramilimab (n=134) and combination (n=121) treatment arms. The majority (98%) had received prior antineoplastic therapy (median, 3). Four patients experienced dose-limiting toxicities in each treatment arm across various dosing cohorts. No MTD was reached. The RP2D on a 3-week schedule was declared as 400 mg ieramilimab plus 300 mg spartalizumab and, on a 4-week schedule (once every 4 weeks; Q4W), as 800 mg ieramilimab plus 400 mg spartalizumab; tumor target (LAG-3) suppression with 600 mg ieramilimab Q4W was predicted to be similar to the Q4W, RP2D schedule. Treatment-related adverse events (TRAEs) occurred in 75 (56%) and 84 (69%) patients in the single-agent and combination arms, respectively. Most common TRAEs were fatigue, gastrointestinal, and skin disorders, and were of mild severity; seven patients experienced at least one treatment-related serious adverse event in the single-agent (5%) and combination group (5.8%). Antitumor activity was observed in the combination arm, with 3 (2%) complete responses and 10 (8%) partial responses in a mixed population of tumor types. In the combination arm, eight patients (6.6%) experienced stable disease for 6 months or longer versus six patients (4.5%) in the single-agent arm. Responding patients trended towards having higher levels of immune gene expression, including CD8 and LAG3, in tumor tissue at baseline. - Conclusions Ieramilimab was well tolerated as monotherapy and in combination with spartalizumab. The toxicity profile of ieramilimab in combination with spartalizumab was comparable to that of spartalizumab alone. Modest antitumor activity was seen with combination treatment. - Trial registration number NCT02460224. | ||
| 650 | 4 | |a combination | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a immunotherapy | |
| 700 | 1 | |a Tan, Daniel S.-W. |e VerfasserIn |0 (DE-588)1265036144 |0 (DE-627)1813970424 |4 aut | |
| 700 | 1 | |a Martín, Miguel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ochoa-de-Olza, María |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sarantopoulos, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carvajal, Richard D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kyi, Chrisann |e VerfasserIn |4 aut | |
| 700 | 1 | |a Esaki, Taito |e VerfasserIn |4 aut | |
| 700 | 1 | |a Prawira, Amy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Akerley, Wallace |e VerfasserIn |4 aut | |
| 700 | 1 | |a Braud, Filippo De |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hui, Rina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhang, Tian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soo, Ross A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maur, Michela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weickhardt, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krauß, Jürgen |d 1960- |e VerfasserIn |0 (DE-588)120665301 |0 (DE-627)70490778X |0 (DE-576)292329083 |4 aut | |
| 700 | 1 | |a Deschler-Baier, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lau, Allen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Samant, Tanay S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Longmire, Tyler |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chowdhury, Niladri Roy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sabatos-Peyton, Catherine A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Patel, Nidhi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ramesh, Radha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hu, Tiancen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carion, Ana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gusenleitner, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yerramilli-Rao, Padmaja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Askoxylakis, Vasileios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kwak, Eunice L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hong, David S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for ImmunoTherapy of Cancer |d London : BioMed Central, 2013 |g 10(2022), 2, Artikel-ID e003776, Seite 1-13 |h Online-Ressource |w (DE-627)750086335 |w (DE-600)2719863-7 |w (DE-576)383767369 |x 2051-1426 |7 nnas |a Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:2 |g elocationid:e003776 |g pages:1-13 |g extent:13 |a Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies |
| 856 | 4 | 0 | |u https://doi.org/10.1136/jitc-2021-003776 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://jitc.bmj.com/content/10/2/e003776 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220406 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 120665301 |a Krauß, Jürgen |m 120665301:Krauß, Jürgen |d 910000 |d 910100 |d 50000 |e 910000PK120665301 |e 910100PK120665301 |e 50000PK120665301 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 17 | ||
| 999 | |a KXP-PPN1797752944 |e 4112486669 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","title_sort":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies"}],"person":[{"given":"Patrick","role":"aut","family":"Schöffski","display":"Schöffski, Patrick","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Tan, Daniel S.-W.","family":"Tan","role":"aut","given":"Daniel S.-W."},{"role":"aut","given":"Miguel","roleDisplay":"VerfasserIn","family":"Martín","display":"Martín, Miguel"},{"given":"María","role":"aut","family":"Ochoa-de-Olza","display":"Ochoa-de-Olza, María","roleDisplay":"VerfasserIn"},{"given":"John","role":"aut","roleDisplay":"VerfasserIn","display":"Sarantopoulos, John","family":"Sarantopoulos"},{"roleDisplay":"VerfasserIn","family":"Carvajal","display":"Carvajal, Richard D.","role":"aut","given":"Richard D."},{"role":"aut","given":"Chrisann","roleDisplay":"VerfasserIn","display":"Kyi, Chrisann","family":"Kyi"},{"roleDisplay":"VerfasserIn","family":"Esaki","display":"Esaki, Taito","role":"aut","given":"Taito"},{"given":"Amy","role":"aut","display":"Prawira, Amy","family":"Prawira","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Akerley","display":"Akerley, Wallace","role":"aut","given":"Wallace"},{"roleDisplay":"VerfasserIn","family":"Braud","display":"Braud, Filippo De","given":"Filippo De","role":"aut"},{"given":"Rina","role":"aut","display":"Hui, Rina","family":"Hui","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Tian","roleDisplay":"VerfasserIn","family":"Zhang","display":"Zhang, Tian"},{"roleDisplay":"VerfasserIn","display":"Soo, Ross A.","family":"Soo","given":"Ross A.","role":"aut"},{"display":"Maur, Michela","family":"Maur","roleDisplay":"VerfasserIn","given":"Michela","role":"aut"},{"family":"Weickhardt","display":"Weickhardt, Andrew","roleDisplay":"VerfasserIn","role":"aut","given":"Andrew"},{"role":"aut","given":"Jürgen","roleDisplay":"VerfasserIn","display":"Krauß, Jürgen","family":"Krauß"},{"roleDisplay":"VerfasserIn","family":"Deschler-Baier","display":"Deschler-Baier, Barbara","given":"Barbara","role":"aut"},{"given":"Allen","role":"aut","roleDisplay":"VerfasserIn","display":"Lau, Allen","family":"Lau"},{"roleDisplay":"VerfasserIn","display":"Samant, Tanay S.","family":"Samant","given":"Tanay S.","role":"aut"},{"role":"aut","given":"Tyler","roleDisplay":"VerfasserIn","display":"Longmire, Tyler","family":"Longmire"},{"given":"Niladri Roy","role":"aut","display":"Chowdhury, Niladri Roy","family":"Chowdhury","roleDisplay":"VerfasserIn"},{"family":"Sabatos-Peyton","display":"Sabatos-Peyton, Catherine A.","roleDisplay":"VerfasserIn","role":"aut","given":"Catherine A."},{"display":"Patel, Nidhi","family":"Patel","roleDisplay":"VerfasserIn","role":"aut","given":"Nidhi"},{"roleDisplay":"VerfasserIn","display":"Ramesh, Radha","family":"Ramesh","role":"aut","given":"Radha"},{"role":"aut","given":"Tiancen","roleDisplay":"VerfasserIn","family":"Hu","display":"Hu, Tiancen"},{"role":"aut","given":"Ana","display":"Carion, Ana","family":"Carion","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Daniel","roleDisplay":"VerfasserIn","display":"Gusenleitner, Daniel","family":"Gusenleitner"},{"given":"Padmaja","role":"aut","roleDisplay":"VerfasserIn","display":"Yerramilli-Rao, Padmaja","family":"Yerramilli-Rao"},{"given":"Vasileios","role":"aut","roleDisplay":"VerfasserIn","display":"Askoxylakis, Vasileios","family":"Askoxylakis"},{"role":"aut","given":"Eunice L.","roleDisplay":"VerfasserIn","family":"Kwak","display":"Kwak, Eunice L."},{"display":"Hong, David S.","family":"Hong","roleDisplay":"VerfasserIn","given":"David S.","role":"aut"}],"note":["Gesehen am 07.04.2022"],"recId":"1797752944","physDesc":[{"extent":"13 S."}],"language":["eng"],"id":{"doi":["10.1136/jitc-2021-003776"],"eki":["1797752944"]},"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 29.06.20"],"part":{"volume":"10","pages":"1-13","year":"2022","text":"10(2022), 2, Artikel-ID e003776, Seite 1-13","issue":"2","extent":"13"},"title":[{"subtitle":"official journal of the Society for Immunotherapy of Cancer (SITC)","title":"Journal for ImmunoTherapy of Cancer","title_sort":"Journal for ImmunoTherapy of Cancer"}],"origin":[{"publisher":"BioMed Central","dateIssuedDisp":"2013-","publisherPlace":"London","dateIssuedKey":"2013"}],"recId":"750086335","pubHistory":["1.2013 -"],"disp":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesJournal for ImmunoTherapy of Cancer","id":{"zdb":["2719863-7"],"issn":["2051-1426"],"eki":["750086335"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Patrick Schöffski, Daniel SW Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak, David S Hong"]},"origin":[{"dateIssuedDisp":"February 25, 2022","dateIssuedKey":"2022"}]} | ||
| SRT | |a SCHOEFFSKIPHASEIIIST2520 | ||